Adoa News Adoa News
Related Articles
New global HIV projections and advances in STI and HIV pre-exposure prophylaxis also unveiled ahead of AIDS 2024, the 25th International AIDS Conference
18 July 2024 (Munich, Germany) – A unique HIV cure case will be among the scientific highlights of AIDS 2024, the 25th International AIDS Conference, which will take place in Munich, Germany and virtually from 22 to 26 July.
For the first time, scientists will share information about the “next Berlin Patient”, who appears to be the world’s seventh person cured of HIV following a stem cell transplant. This is the first HIV cure case in which the donor had a single, rather than double, CCR5-delta32 mutation, which could have promising implications for future research.
Other scientific highlights include:
- UNAIDS-led projections showing that without bold action, there could be nearly 35 million new HIV acquisitions and nearly 18 million AIDS-related deaths between 2021 and 2050
- Research suggesting that doxycycline pre-exposure prophylaxis (DoxyPrEP) is a promising strategy for preventing sexually transmitted infections (STIs)
- A study suggesting that less frequent monitoring visits could reduce the burden on HIV PrEP users without increasing STIs
- Real-world evidence that long-acting injectable cabotegravir (CAB-LA) is a popular and feasible HIV prevention option for women and men in Africa
AIDS 2024 will also include a presentation with late-breaking full results from the PURPOSE 1 trial of long-acting injectable lenacapavir for HIV prevention. Last month, topline results from an interim analysis of the trial indicated that injectable lenacapavir demonstrated 100% efficacy for HIV prevention in cisgender women.
“We’re seeing impressive innovation across the entire spectrum of HIV research,” Sharon Lewin, President of IAS – the International AIDS Society, AIDS 2024 International Co-Chair and Director of the Peter Doherty Institute for Infection and Immunity at the University of Melbourne in Australia, said. “For these advances to have a real-world impact, we must put people first and keep delivery and access concerns front and centre.”
Hosted by the IAS, AIDS 2024 will bring together thousands of scientists, policy makers and advocates to examine the latest advances in HIV research and forge a more equitable and innovative HIV response. This year’s conference will call on the global HIV community to unite behind a simple principle: Put people first!
“In every aspect of the HIV response, people living with and affected by HIV must be not just beneficiaries, but the actors driving our efforts,” Lewin said.
Today’s scientific highlights press conference featured six studies selected from the thousands of abstracts that will be presented next week.
